CYP3A4 and cancer: After expanding the dataset of Molenaar-Kuijsten to include 3 additional approved oral anti-cancer drugs (fuzuloparib [23, 24], pirtobrutinib [25], and fedratinib [26]) metabolized by CYP3A, we applied this approach in the opposite direction (lack of clinical data for the effect of strong CYP3A4 inducers) given available clinical DDI data generated in this study for encorafenib (Table 3).